This information was published on 2026-06-18T16:03:01 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2662128 |
| (220) |
12 Jun 2026
|
| (300) |
US, 17 Dec 2025, 99553113
|
| (511) (510) |
Class 5
Pharmaceutical preparations for use in the treatment of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, prostate, pancreatic, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders, including castration resistant prostate cancer; Pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders; Pharmaceutical preparations for use in the treatment of metastatic diseases; Pharmaceutical preparations for treating metabolic diseases and disorders; Pharmaceutical preparations for treating inflammatory and autoimmune diseases and diseases; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular diseases and disorders; Pharmaceutical preparations. |
| (540) | BYSTEAPIX |
| (550) | Word |
| (730) |
Amgen Inc.
|
| (750) |
Spruson & Ferguson
|
Find out more about publications on the About page.